Accessibility Menu

Zoetis(FRA) ZOE

Market Cap€27.64BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)+205%
5 Year-62%
1 Year-50%
1 Month-1%
€66.10
-1.17%
-0.78Today
Zoetis last closing stock price
MetricPriceDate
Last closeEUR 66.042026-08-31
Zoetis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.55%EUR 65.682026-08-24
1 month-0.54%EUR 66.402026-07-31
3 month+1.76%EUR 64.902026-06-02
Year to date-38.45%EUR 107.302025-12-30
1 year-50.3%EUR 132.882025-08-29
3 year-63.01%EUR 178.552023-09-01
5 year-61.83%EUR 173.002021-09-01
Since inception+204.9%EUR 21.942013-02-11

Zoetis Financials at a Glance

Market Cap

€27.64BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€8.16K

Net Income (TTM)

€2.24K

EPS (TTM)

€5.21

P/E Ratio

12.83

Dividend

€1.80

Beta (Volatility)

-0.02 (Low)

Price

€66.10

Volume

159

Open

€66.52

Previous Close

€66.10

Daily Range

€65.42 - €66.54

52-Week Range

€61.94 - €134.00

Estimated Earnings Date

N/A

ZOE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U.S. market and regulatory activities. The International segment includes non-U.S. market and regulatory activities. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Industry

Pharmaceuticals

Employees

14,500

CEO

Kristin C. Peck, MBA

ZOE Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

64.15%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

7.79%

Dividend Yield

2.69%

Payout Ratio

N/A

Stock Overview

Market Cap

€27.64BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

413.22M

Volume

159

Avg. Volume

519.136

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Zoetis Performance Analysis

Zoetis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 7,688,104,14516.9%
20232023-12-31EUR 7,902,947,6372.8%
20242024-12-31EUR 8,556,974,2988.3%
20252025-12-31EUR 8,388,432,536-2.0%
Zoetis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 4.2818.3%
20232023-12-31EUR 4.699.7%
20242024-12-31EUR 5.057.7%
20252025-12-31EUR 5.345.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€2.12K

+1.0%

Gross Profit

€1.52K

+1.0%

Gross Margin

71.47%

+1.0%

Market Cap

€27.64BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€1.82

N/A

Employees

14,500

N/A

Net Income

€594.30

+0.9%

EBITDA

€961.55

+1.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€9.37K

+33.7%

Total Debt

€8.08K

+1.4%

Accounts Receivable

€1.37K

+1.0%

Inventory

€2.25K

+1.1%

Long Term Debt

€8.08K

+1.7%

Short Term Debt

€0.00

+0.0%

Return on Assets

17.58%

+0.9%

Return on Invested Capital

20.51%

+1.1%

Free Cash Flow

€464.26

+1.9%

Operating Cash Flow

€565.47

+1.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About ZOE

What is the current price of Zoetis?

Zoetis is trading at €66.10 per share.

What is the 52-week range for Zoetis?

Over the past 52 weeks, Zoetis has traded between €61.94 and €134.00.

How much debt does Zoetis have?

As of the most recent reporting period, Zoetis reported total debt of €8.08B.

How much cash does Zoetis have on hand?

Zoetis reported €1.29B in cash and cash equivalents in its most recent financial results.

What is Zoetis’s dividend yield?

Zoetis currently has a dividend yield of 2.69%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.